人福醫藥(600079.SH)：擬出售鍾祥市人民醫院新院區不動產
格隆匯12月30日丨人福醫藥(600079.SH)公佈，公司全資子公司人福鍾祥醫療管理有限公司(“鍾祥醫療”)與鍾祥市興瑞資產經營管理有限公司(“興瑞資產”)簽署《資產購買協議》，鍾祥醫療擬將其所持有的位於鍾祥市南湖新區347國道以北、鍾祥至武荊高速連接線以西的鐘祥市人民醫院新院區的房地產、裝修、附屬物及地上附着物(“鍾祥市人民醫院新院區不動產”)出售給興瑞資產，出售總價款將根據工程決算審計結果來確定，興瑞資產先行支付部分出售價款人民幣6.7億元，工程決算審計結果認定的出售總價款與6.7億元之間的差額部分，鍾祥醫療仍享有按此前與鍾祥市人民政府約定的8%的比例收取管理費(含租賃費)的權利。
“十二五”期間，根據《關於促進健康服務業發展的若干意見》(國發[2013]40號)、《關於加快發展社會辦醫的若干意見》(國衞體改發[2013]54號)等文件鼓勵社會資本參與公立醫院改革的精神，公司在湖北省通過收購、合作、新建等形式拓展醫療服務產業，計劃佈局區域型醫療服務網絡，一方面通過下屬控股子公司進一步拓展藥品、器械、耗材等配送業務，另一方面結合當地醫療服務需求開展延伸性業務，從而打通公司從醫藥生產、流通到醫療服務的全產業鏈經營能力，提高整體經營業績。在此背景下，2014年公司與鍾祥市人民政府展開關於鍾祥市人民醫院的合作項目，公司下屬控股子公司人福醫藥鍾祥有限公司為鍾祥市人民醫院提供配送服務，年銷售額由合作初期的約7000萬元增長至約1.5億元，是該院藥品、醫用耗材供應鏈的主要供應商。
2018年以來，為提升資產運營效率和抗風險能力，公司堅定實施“歸核化”戰略，積極推進業務聚焦與資產優化，決定逐步退出醫療服務等競爭優勢不明顯或協同效應較弱的細分領域。經與鍾祥市人民政府協商一致，由興瑞資產實施鍾祥市人民醫院新院區的回購事宜。鍾祥市人民醫院新院區不動產的交易金額將按工程決算審計結果確認，經初步測算，該項目投資收益約4000萬元。此次出售鍾祥市人民醫院新院區不動產所得款項將用於公司生產經營活動，包括但不限於償還公司有息債務以及補充公司及控股子公司的營運資金等，有利於公司集中資源發展具有競爭優勢的細分領域。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
